Just like medicine, diseases also tend to evolve and become resistant to some of the existing therapeutics. For this reason, biopharmaceutical companies innovate and check on the efficacy of the products they market.
Cidara Therapeutics, Inc. is one of the biotechnology companies that focus its resources on the discovery, development and commercialization of novelty therapeutics. The offerings of the company are focused on anti-infectives. These compounds are used in the treatment of diseases that are now inadequately address by existing standard of care therapies. The company has two lead products, CD101 IV and CD101 topical. The former is used in the treatment of systemic fungal infections, while the latter is a topical formation for vulvovaginal candidiasis.
The company was formerly known as K2 Therapeutics, Inc. It holds its corporate office in San Diego, California and remains publicly traded on the NASDAQ Global Market. Common shares of the business are marketed using the ticker symbol CDTX.
No comments:
Post a Comment